Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of Retosiban Versus Placebo as Add-on Therapy for Women in Spontaneous Preterm Labor
Phase of Trial: Phase III
Latest Information Update: 03 Nov 2017
At a glance
- Drugs Retosiban (Primary)
- Indications Preterm labour
- Focus Registrational; Therapeutic Use
- Acronyms NEWBORN-1
- Sponsors GlaxoSmithKline
- 11 Jul 2017 Planned End Date changed from 21 Nov 2019 to 21 Jul 2017.
- 11 Jul 2017 Planned primary completion date changed from 21 Nov 2019 to 21 Jul 2017.
- 14 Jun 2017 Planned End Date changed from 14 May 2019 to 21 Nov 2019.